NCT05654948

Brief Summary

The investigators will include patients suffering from Major Depressive Disorder (MDD), in episode. The patients will undertake neuropsychological tasks evaluating executive function and clinical assessment related to depressive symptoms, anxiety, transdiagnostic symptoms and psychological skills.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 25, 2022

Completed
21 days until next milestone

First Posted

Study publicly available on registry

December 16, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

February 9, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 25, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 25, 2024

Completed
Last Updated

December 9, 2024

Status Verified

December 1, 2024

Enrollment Period

1.2 years

First QC Date

November 25, 2022

Last Update Submit

December 4, 2024

Conditions

Keywords

depressionfundamental decisioncomputerised cognitive performance test

Outcome Measures

Primary Outcomes (5)

  • MADRS score

    The severity of the depression will be assessed using the MADRS score. Montgomery-Asberg Depression Scale (MADRS) The scale has 10 items rated from 0 to 6. 0 to 6 points: the patient is considered healthy. 7 to 19 points: the patient is considered to be in mild depression. 20 to 34 points: the patient is considered to be in moderate depression. \> 34 points: the patient is considered to be in severe depression.

    baseline

  • Simple reaction time (SRT) obtained at the MindPulse test

    The "simple reaction time" (SRT) is the reaction time to the first test (the subject releases the mouse click as quickly as possible when an image appears) , it contains the time needed to perceive and analyse the image, to formulate the response and to execute the motor response.

    Baseline

  • Go/NoGo score obtained at the MindPulse test

    reaction time with a categorisation where the subject must react or not react (Go/NoGo) according to the categorical target, in this case a light or dark colour (white coloured image or grey coloured image).

    Baseline

  • Executive speed (ES) obtained at the MindPulse test

    The ES Score corresponds to the Executive Speed, i.e. the average time of categorisation of the subject.

    Baseline

  • Reaction to difficulty obtained at the MindPulse test

    It corresponds to the adaptation of the subject to the level of difficulty. The shift of the circle above the blue rectangle indicates a higher than expected slowing down in reaction to the difficulty of the instruction, while a shift below the blue rectangle indicates that the participant is not slowing down enough in response to the difficulty and is at risk of making mistakes.

    Baseline

Secondary Outcomes (7)

  • Level of anxiety

    Baseline

  • clinical characterisation

    Baseline

  • clinical characterisation

    Baseline

  • insomnia severity

    Baseline

  • Stroop test

    Baseline

  • +2 more secondary outcomes

Interventions

In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty

Also known as: MindPulse

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

people suffering from a characterised depressive episode

You may qualify if:

  • Age between 18 and 65 years.
  • Diagnosis of a depressive episode according to DSM-5 criteria, confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0 according to DSM-5).
  • No evidence of bipolar disorder or schizophrenia, confirmed by the MINI.
  • No dementing neurological disease.
  • No guardianship or trusteeship

You may not qualify if:

  • Opposition to data processing
  • Depressive episode in the context of a known bipolar disorder or schizophrenic illness

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinique psychiatrique universitaire

Tours, 37044, France

Location

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Wissam EL HAGE

    CHU Tours

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 25, 2022

First Posted

December 16, 2022

Study Start

February 9, 2023

Primary Completion

April 25, 2024

Study Completion

April 25, 2024

Last Updated

December 9, 2024

Record last verified: 2024-12

Locations